(0.01%) 5 479.00 points
(-0.01%) 38 814 points
(0.05%) 19 932 points
(0.26%) $80.54
(0.97%) $2.82
(0.12%) $2 331.80
(-0.33%) $29.30
(-0.03%) $970.60
(0.04%) $0.932
(-0.10%) $10.64
(0.09%) $0.788
(-1.87%) $86.80
Live Chart Being Loaded With Signals
CymaBay Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on developing and providing therapies to treat liver and other chronic diseases...
Stats | |
---|---|
Šios dienos apimtis | 8.35M |
Vidutinė apimtis | 3.94M |
Rinkos kapitalizacija | 3.73B |
EPS | $-0.370 ( Q4 | 2024-02-28 ) |
Kita pelno data | ( $0 ) 2024-08-08 |
Last Dividend | $0 ( N/A ) |
Next Dividend | $0 ( N/A ) |
P/E |
-32.81 (Sector) 42.63 (Industry) 24.32 |
ATR14 | $0.00700 (0.02%) |
Date | Person | Action | Amount | type |
---|---|---|---|---|
2024-03-22 | Loewy Caroline M | Sell | 30 000 | Employee Stock Option (right to buy) |
2024-03-22 | Loewy Caroline M | Sell | 15 000 | Employee Stock Option (right to buy) |
2024-03-22 | Loewy Caroline M | Sell | 7 500 | Employee Stock Option (right to buy) |
2024-03-22 | Loewy Caroline M | Sell | 16 000 | Employee Stock Option (right to buy) |
2024-03-22 | Loewy Caroline M | Sell | 27 705 | Employee Stock Option (right to buy) |
INSIDER POWER |
---|
-97.48 |
Last 100 transactions |
Buy: 127 470 | Sell: 9 848 383 |
Tūris Koreliacija
Cymabay Therapeutics Inc Koreliacija
10 Labiausiai neigiamai susiję koreliacijos |
---|
Ar žinojote?
Koreliacija yra statistinis rodiklis, aprašantis ryšį tarp dviejų kintamųjų. Jis svyruoja nuo -1 iki 1, kur -1 reiškia tobulo neigiamo ryšio koreliaciją (padidėjus vienam kintamajam, sumažėja kitas), 1 reiškia tobulo teigiamo ryšio koreliaciją (padidėjus vienam kintamajam, padidėja ir kitas), o 0 reiškia jokios koreliacijos (tarp kintamųjų nėra jokio ryšio).
Koreliacija gali būti naudojama analizuojant bet kurių dviejų kintamųjų ryšį, ne tik akcijų. Jis dažnai naudojamas finansų, ekonomikos, psichologijos ir kitose srityse.
Cymabay Therapeutics Inc Koreliacija - Valiuta/Žaliavos
Cymabay Therapeutics Inc Finansinės ataskaitos
Annual | 2023 |
Pajamos: | $31.07M |
Bruto pelnas: | $30.39M (97.81 %) |
EPS: | $-0.990 |
FY | 2023 |
Pajamos: | $31.07M |
Bruto pelnas: | $30.39M (97.81 %) |
EPS: | $-0.990 |
FY | 2022 |
Pajamos: | $0 |
Bruto pelnas: | $-710 000 (0.00 %) |
EPS: | $-1.350 |
FY | 2021 |
Pajamos: | $0.00 |
Bruto pelnas: | $0.00 (0.00 %) |
EPS: | $-1.304 |
Financial Reports:
No articles found.
Contract Name | Last Trade Date (EDT) | Strike | Last Price | Bid | Ask | Change | % Change | Volume | Open Interest | Implied Volatility | Strike Date |
---|---|---|---|---|---|---|---|---|---|---|---|
No data available |
Contract Name | Last Trade Date (EDT) | Strike | Last Price | Bid | Ask | Change | % Change | Volume | Open Interest | Implied Volatility | Strike Date |
---|---|---|---|---|---|---|---|---|---|---|---|
No data available |
Cymabay Therapeutics Inc
CymaBay Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on developing and providing therapies to treat liver and other chronic diseases. Its lead product candidate is seladelpar (MBX-8025), a selective agonist of peroxisome proliferator activated receptor delta that is in phase III clinical study for the treatments of primary biliary cholangitis (PBC), as well as has completed Phase 2b clinical study to treat patients with nonalcoholic steatohepatitis. The company also develops MBX-2982, which is in Phase 2a clinical study for the disease/condition of hypoglycemia in type 1 diabetics. It has a license agreement with ABW Cyclops SPV LP to support development of seladelpar for the treatment of PBC; and holds a worldwide license from Janssen Pharmaceuticals, Inc. to research, develop, and commercialize compounds with activity against an undisclosed metabolic disease target. The company was formerly known as Metabolex, Inc. CymaBay Therapeutics, Inc. was incorporated in 1988 and is headquartered in Newark, California.
Apie Signalai gyvai
Šiame puslapyje pateikti tiesioginiai signalai padeda nustatyti, kada PIRKTI ar PARDUOTI NA. Signalai vėluoja 1 minutę; kaip ir su visais rinkos signalais, taip ir su šiais, visuomet yra klaidų tikimybė.
Tiesioginiai prekybos signalai nėra apibrėžti, todėl getagraph.com neprisiima atsakomybės už jokius veiksmus, kurių buvo imtasi žinant šiuos signalus, kaip aprašyta Naudojimo sąlygose. Signalai yra pagrįsti įvairiais techninės analizės rodikliais.